In this episode of Healthcare Matters, Dr. Robert Popovian and Ben Blanc sit down with Dr. Alison Bailey, Chief of Cardiology for Centennial Heart at Parkridge in Chattanooga, Tennessee and a Physician Director of Cardiovascular Disease for HCA Healthcare, to explore how policy decisions can help—or hinder—innovation in cardiovascular care.

They discuss the hidden consequences of the Inflation Reduction Act (IRA) for small molecule drug development, the promise of gene-targeted therapies like siRNA, and why medical research funding remains vital for turning new science into life-saving treatments.

Tune in to learn why smarter incentives and stable funding are key to tackling America’s growing cardiovascular crisis.

Among the highlights in this episode:

03:28: Dr. Bailey shares her passion for cardiovascular prevention, emphasizing how patient education and access shape outcomes

04:12: Dr. Bailey discusses the concerning rise in cardiovascular death rates in the U.S. despite advances in treatment, pointing to lifestyle factors and health inequities

05:35: Ben asks about the impact of small molecule therapies in cardiology and how the Inflation Reduction Act may affect future drug development

06:04: Dr. Popovian explains how the IRA’s Maximum Fair Price (MFP) policy shortens market exclusivity for small molecules, reducing incentives for new cardiovascular treatments

08:40: Dr. Bailey expands on how genetically targeted small molecules, like siRNA therapies, are game-changers for cholesterol and rare cardiac conditions, but policy must support their development

10:50: Ben asks about the consequences for patients if companies shift focus away from small molecules. Dr. Bailey warns that fewer innovations could limit treatment options and worsen health disparities

12:15: Dr. Popovian explains how small molecules remain essential for oral medications that improve adherence, affordability, and widespread access—especially in chronic conditions like heart disease

13:00: Ben brings up the bipartisan MINI Act, which aims to align protections for certain targeted small molecule therapies with biologics to maintain incentives for innovation

14:45: Dr. Bailey supports the MINI Act as a practical fix that would encourage more investment in next-generation therapies and benefit cardiovascular patients

16:20: Dr. Popovian highlights the risk of medical research funding cuts, stressing that NIH funding drives discoveries that pharma can’t tackle alone

18:05: Dr. Bailey gives real-world examples of now-standard heart medications that came from decades of NIH and industry collaboration, underscoring the need for stable funding

19:00: Dr. Popovian adds that even widely used generic drugs like beta blockers for heart failure exist today because of federally funded research

20:40: Dr. Popovian and Dr. Bailey agree that more clinician voices are needed to help policymakers see the real impact of drug policy on patient care

22:00: Dr. Bailey closes by stressing that these therapies are not hypothetical—they are real and available now but require supportive policy to reach all patients who need them

Contact Our Hosts

Dr. Robert Popovian, Chief Science Policy Officer at GHLF: rpopovian@ghlf.org

Ben Blanc, Director, Digital Production and Engagement at GHLF: bblanc@ghlf.org

A podcast series produced by Ben Blanc.

We want to hear what you think. Send your comments, or a video or audio clip of yourself, to podcasts@ghlf.org

Listen to all episodes of Healthcare Matters on our website or on your favorite podcast channel.

See omnystudio.com/listener for privacy information.

S6, Ep 7- Cardiovascular Breakthroughs and Policy Pitfalls: A Conversation with Dr. Alison Bailey